Literature DB >> 26328632

Enhanced Steroid Therapy in Adult Minimal Change Nephrotic Syndrome: A Systematic Review and Meta-analysis.

Lingfei Zhao1, Jun Cheng, Jingyi Zhou, Congcong Wu, Jianghua Chen.   

Abstract

The best regimen for adult minimal change nephrotic syndrome (MCNS) is still unknown. Due to an excessive number of adverse events caused by oral steroid monotherapy, enhanced steroid therapy (low dose of prednisolone with a short course of methylprednisolone or with another immunosuppressant) has been studied extensively for years. In this study, the PubMed, Embase, EBSCO and Cochrane Library databases were searched for clinical trials which compared enhanced steroid therapy with oral steroid monotherapy in adult MCNS and a meta-analysis was performed. Seven studies involving 357 patients were included. We found that patients treated with enhanced steroid therapy responded more quickly to complete remission (CR) [mean difference = -9.52, 95% confidence interval (CI): -12.66--6.39, p<0.00001] and showed fewer adverse events [risk radio (RR) = 0.72, 95% CI: 0.54-0.97, p=0.03] than patients receiving oral steroid monotherapy. The CR rate (RR= 0.96, 95% CI: 0.83-1.10, p=0.53) and relapse rate (RR=0.87, 95% CI: 0.57-1.34, p=0.53) were similar in both groups.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26328632     DOI: 10.2169/internalmedicine.54.3927

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Adult-onset minimal change disease: the significance of histological chronic changes for clinical presentation and outcome.

Authors:  Gabriel Stefan; Ruxandra Busuioc; Simona Stancu; Madalina Hoinoiu; Adrian Zugravu; Nicoleta Petre; Gabriel Mircescu
Journal:  Clin Exp Nephrol       Date:  2020-10-22       Impact factor: 2.801

2.  Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial.

Authors:  Nicholas Rhys Medjeral-Thomas; Christopher Lawrence; Marie Condon; Bhrigu Sood; Paul Warwicker; Heather Brown; James Pattison; Sunil Bhandari; Jonathan Barratt; Neil Turner; H Terence Cook; Jeremy B Levy; Liz Lightstone; Charles Pusey; Jack Galliford; Thomas D Cairns; Megan Griffith
Journal:  Clin J Am Soc Nephrol       Date:  2020-01-17       Impact factor: 8.237

3.  Steroid Pulse Therapy for De Novo Minimal Change Disease During Pregnancy.

Authors:  Hiroshi Sato; Yuna Asami; Reona Shiro; Masato Aoki; Miki Yasuda; Saeko Imai; Rie Sakai; Kenji Oida; Kanako Kawaharamura; Hiroko Yano; Nao Taguchi; Takako Suzuki; Masaya Hirose
Journal:  Am J Case Rep       Date:  2017-04-18

4.  A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN).

Authors:  Tilde Kristensen; Henrik Birn; Per Ivarsen
Journal:  Trials       Date:  2021-07-12       Impact factor: 2.279

5.  A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.

Authors:  Keisuke Horikoshi; Norihiko Sakai; Naoki Yamamoto; Hisayuki Ogura; Koichi Sato; Taro Miyagawa; Shinji Kitajima; Tadashi Toyama; Akinori Hara; Yasunori Iwata; Miho Shimizu; Kengo Furuichi; Takashi Wada
Journal:  BMC Nephrol       Date:  2020-09-29       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.